Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Goh, Hyun Gil | - |
dc.contributor.author | Lee, Young-Sun | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Lee, Min-Goo | - |
dc.contributor.author | An, Hyunggin | - |
dc.contributor.author | Jeen, Yoon Tae | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.date.accessioned | 2021-11-18T07:40:57Z | - |
dc.date.available | 2021-11-18T07:40:57Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-06-12 | - |
dc.identifier.issn | 1471-230X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/127849 | - |
dc.description.abstract | Background: Natural killer (NK) cells have been known to contribute to surveillance and control of hepatocellular carcinoma (HCC). However, the association of NK cell activity with stage and recurrence risk of HCC have not been fully evaluated. Methods: Untreated patients with newly diagnosed HCC were prospectively enrolled. Peripheral blood mononuclear cells were isolated at the time of diagnosis. Patients who had undergone surgery or radiofrequency ablation were classified as the curative treatment group, and their blood samples were collected again at 1 month after treatment. Results: A total of 80 patients with HCC were enrolled. The mean age was 62.5 years. At baseline, interferon (IFN)-gamma producing NK cell proportion was significantly lower in patients with Barcelona clinic liver cancer (BCLC) stage B, C, or D than in those with BCLC stage 0 (42.9% vs. 56.8%, P = 0.045). Among all patients, 56 patients had undergone curative treatment, and 42 patients re-visited at 1 month after curative treatment. There was no significant change in total NK cell and IFN-gamma producing NK cell proportion from baseline to 1 month after treatment (all P > 0.05). During a median follow-up of 12.4 months, HCC recurred in 14 patients (33.3%). When patients were classified according to the IFN-gamma producing NK cell proportion (group 1, >= 45%; and group 2, < 45%), HCC recurrence rate did not differ according to the IFN-gamma producing NK cell proportion at baseline (log-rank test, P = 0.835). However, patients with < 45% IFN-gamma producing NK cell proportion at 1 month after treatment had a significantly higher HCC recurrence rate than patients with that of >= 45% (log-rank test, P < 0.001). Multivariate analysis revealed that BCLC stage B (hazard ratio [HR] = 3.412, P = 0.045) and < 45% IFN-gamma producing NK cell proportion at 1 month after treatment (HR = 6.934, P = 0.001) independently predicted an increased risk of HCC recurrence. Conclusions: Decreased NK cell activity is significantly associated with the advanced stage of HCC, and the increased recurrence risk of HCC after curative treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.subject | LONG-TERM SURVIVAL | - |
dc.subject | PROGNOSTIC-FACTORS | - |
dc.subject | LIVER | - |
dc.subject | MACROPHAGES | - |
dc.subject | DYSFUNCTION | - |
dc.subject | IMMUNOLOGY | - |
dc.subject | RESECTION | - |
dc.subject | PROMOTE | - |
dc.subject | INNATE | - |
dc.title | Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young-Sun | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.identifier.doi | 10.1186/s12876-021-01833-2 | - |
dc.identifier.scopusid | 2-s2.0-85107878063 | - |
dc.identifier.wosid | 000663032000001 | - |
dc.identifier.bibliographicCitation | BMC GASTROENTEROLOGY, v.21, no.1 | - |
dc.relation.isPartOf | BMC GASTROENTEROLOGY | - |
dc.citation.title | BMC GASTROENTEROLOGY | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | LONG-TERM SURVIVAL | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | LIVER | - |
dc.subject.keywordPlus | MACROPHAGES | - |
dc.subject.keywordPlus | DYSFUNCTION | - |
dc.subject.keywordPlus | IMMUNOLOGY | - |
dc.subject.keywordPlus | RESECTION | - |
dc.subject.keywordPlus | PROMOTE | - |
dc.subject.keywordPlus | INNATE | - |
dc.subject.keywordAuthor | Natural killer cell | - |
dc.subject.keywordAuthor | Interferon-gamma | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Stage | - |
dc.subject.keywordAuthor | Recurrence | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.